Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Granulocytapheresis Plus Steroids vs Steroids Alone in Active Steroid Dependant Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 - 75 years old~* Active ulcerative colitis with documented clinical symptoms and endoscopic findings~* Active disease defined as DAI (Mayo score) ≥ 4 and ≤10 with at least 1 point in flexible sigmoidoscopy~* Steroid dependency as defined by:~A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease~B. appearance of relapse within 3 months after withdrawal of corticosteroids~* Colonic involvement with ulcerative colitis beyond 15cm of the anal verge~* Stable doses:A. Aminosalicylates for the last 4 weeks B. Prednisolone or equivalent dose ≤ 20 mg/day for the last 2 weeks C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks~* Signed informed consent form~* Agree to participate in the required follow-up visits~* Able to complete the diary~Exclusion Criteria:~* Febrile (\> 38ºC)~* Evidence of toxic megacolon~* Anticipated need for surgery within 24 weeks~* Known obstructive diseases of the gastrointestinal system~* Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis~* A history of allergic reaction to heparin or heparin-induced thrombocytopenia~* A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures~* Requires a central venous access catheter for the apheresis treatments~* Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV~* Hypotension (systolic blood pressure \<80 mmHg and/or diastolic blood pressure \<50 mmHg) at screening visit only~* Uncontrolled hypertension (systolic blood pressure \>180 mmHg or diastolic blood pressure \>120 mmHg) despite medical therapy~* A history of myocardial infarction or unstable angina within the past 6 months~* A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months~* Prosthetic heart valve, pacemaker or other permanent implant~* Severe cardiovascular or peripheral vascular disease, severe renal disease~* Liver disease defined as levels of SGOT \[AST\], SGPT \[ALT\] or alkaline phosphatase \>2.5x the upper limit of the normal range for the laboratory performing test~* History of cirrhosis~* Known bleeding disorder (PT or PTT\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment~* Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis~* Known infection with Hepatitis B or C, or HIV~* Abnormal hematology parameters defined as severe anemia with hemoglobin \<8.5g/dL, white blood cell count of \<3,500/μl and a granulocyte count \< 2,000/μl~* Fibrinogen level \>700mg/dL~* Major surgery within the past 6 months~* Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections~* Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II)~* History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\> 10 años)~* Current drug or alcohol abuse~* Pregnant, lactating or planning to become pregnant during the course of the clinical investigation~* Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic~* Received cyclosporine or tacrolimus within the last 8 weeks~* Received infliximab within the last 8 weeks~* Fulminant ulcerative colitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Seven apheresis treatments over seven consecutive weeks (1/week) in conjunction with a starting dose of 40mg of oral prednisone per day at Week 00 for two weeks which will be tapered down to zero 5 mg/week within nine weeks
- 2 (Type: ACTIVE_COMPARATOR): Treatment with starting dose of 40mg of oral prednisone per day at Week 00 for two weeks and tapered down to zero 5 mg/week within nine weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).